Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas

British Journal of Cancer

Volumn 73, Issue 5, 1996, Pages 640-643

  Ellis, P A ^a,b   Makris, A ^b   Burton, S A ^a   Titley, J ^a   Ormerod, M G ^a   Salter, J ^a   Powles, T J ^b   Smith, I E ^b   Dowsett, M ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Breast carcinoma; MIB 1; S phase fraction

Indexed keywords

HORMONE; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEUPLOIDY; ANTIBODY PRODUCTION; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PLOIDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

EID: 0030022712     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.111     Document Type: Article

References (33)

1. CAMPLEJOHN RS, ASH CM, GILLETT CE, RAIKUNDALIA B, BARNES DM, GREGORY WM, RICHARDS MA AND MILLS RR. (1994). The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre. Br. J. Cancer, 71, 140-145.
2. CATTORETTI G, BECKER MHG, KEY G, DUCHROW M, SCHLUTER C, GALLE J AND GERDES J. (1992). Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin fixed paraffin sections. J. Pathol., 168, 357-363.
3. COOMBES RC, GOSS P, DOWSETT M, GAZET JC AND BRODIE H. (1984). 4-hydroxyandrostenedione in advanced breast cancer. Lancet, 2, 1237-1239.
4. DRESSLER LG, SEAMER LC, OWENS MA, CLARK GM AND McGUIRE WL. (1988). DNA flow cytometry and prognostic factors in 1331 frozen cancer specimens. Cancer, 161, 420-427.
5. FERNANDO IN, TITLEY JC, POWLES TJ, DOWSETT M, TROTT PA, ASHLEY SE, FORD HT AND ORMEROD MG. (1994). Measurement of S-phase fraction and ploidy in sequential fine needle aspirates from primary human breast tumours treated with tamoxifen. Br. J. Cancer, 70, 1211-1216.
6. GASPARINI G, BORACCHI P, VERDERIO P AND BEVILACQUA P. (1994). Cell kinetics in human breast cancer: comparisons between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int. J. Cancer, 57, 822-829.
7. GERDES J, LEMKE H, BAISCH H, WACHER HH, SCHWAB U AND STEIN H. (1984). Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol., 168, 357-363.
8. HSU SM, RAINE L AND FANGER H. (1981). Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedure. J. Histochem. Cytochem., 29, 577-580.
9. ISOLA JJ, HELIN HJ, HELLE MJ AND KALLIONIEMI O. (1990). Evaluation of Cell proliferation in breast carcinoma: Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer, 65, 1180-1184.
10. JOHNSTON SRD, McLENNAN KA, SALTER J, SACKS NM, BAUM M, SMITH IE AND DOWSETT M. (1993). Tamoxifen induces the expression of cytoplasmic c-erbB2 immunoreactivity in oestrogen receptor-positive breast carcinomas in vivo. Breast, 2, 93-99.
11. KEY G, BECKER MHG, DUCHROW M, SCHLUTER C AND GERDES J. (1992). New Ki-67 equivalent murine monoclonal antibodies (MIBI-3) prepared against recombinant parts of the Ki-67 antigen. Anal. Cell. Pathol., 4, 181-185.
12. LARSEN JK. (1994). Measurement of cytoplasmic and nuclear antigens. In Flow Cytometry: A Practical Approach, 2nd edn, Ormerod MG. (ed.) pp. 93-100 IRL Press, Oxford University Press: Oxford .
13. LLUNG BM, CHEW K, DENG G, MATSUMURA K, WALDMAN F AND SMITH H. (1994). Fine needle aspiration techniques for the characterization of breast cancers. Cancer, 74, (suppl.) 1000-1005.
14. MANSOUR EG, RAVDIN PM AND DRESSLER L. (1994). Prognostic factors in early breast carcinoma. Cancer, 74, (suppl.) 381-400.
15. 1. Breast Cancer Res. Treat., 17, 155-156.
16. ONDA K, DAVIS RL, SHIBUYA M, WILSON CB AND HOSHINO T. (1994). Correlation between the bromodeoxyuridine labelling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas. Cancer, 74, 1921-1926.
17. ORMEROD MG. (1994). Analysis of DNA - general methods. In Flow Cytometry: A Practical Approach, 2nd edn, Ormerod MG. (ed.) pp 119-135 IRL Press, Oxford University Press: Oxford.
18. PICH A, PONTI R, VALENTE G, CHIUSA L, GEUNA M, NOVERO D AND PALESTRO G. (1994). MIB-1, Ki-67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas. J. Clin. Pathol., 47, 18-22.
19. PINDER SE, WENCYK P, SIBBERING DM, BELL JA, ELSTON CW, NICHOLSON R, ROBERTSON JFR, BLAMEY RW AND ELLIS IO. (1995). Assessment of the new proliferative marker MIB-1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br. J. Cancer, 71, 146-149.
20. REMVIKOS Y, MAGDELENAT H AND ZAJDELA A. (1988). DNA flow cytometry applied to fine needle sampling of human breast cancer. Cancer, 61, 1629-1634.
21. REMVIKOS Y, BEUZEBOC P, ZAJDELA A, VOILLEMOT N, MAGDELENAT H AND POUILLART P. (1989). Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J. Natl Cancer Inst., 81, 1383-1387.
22. SAHIN AA, RO J, RO JY, BLICK MB, EL-NAGGAR, ORDONEZ NG, FRITSCHE HA, SMITH TL, HORTABAGYI GN AND AYALA AG. (1991). Ki-67 immunostaining in node negative stage I/II breast cancer. Cancer, 68, 549-557.
23. SHI SR, KEY ME AND KALRA KL. (1991). Antigenic retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J. Histochem. Cytochem., 39, 741-748.
24. SILVESTRINI R, DAIDONE MG AND GASPARINI G. (1985). Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer, 56, 1982-1987.
25. STAL O, DUFMATS M, HATSCHEK T, CARSTENSEN J, KLINTENBERG C, RUTQUIST LE, SKOOG L, SULLIVAN S, WINGREN S AND NORDESKJOLD B. (1993). S-phase fraction is a prognostic factor in stage I breast carcinoma. J. Clin. Oncol., 11, 1717-1722.
26. TUBIANA M, PEJOVIC MH, CHAVAUDRA N, CONTESSO G AND MALAISE EP. (1984). The long term prognostic significance of thymidine labelling index in breast cancer. Int. J. Cancer, 33, 441-445.
27. VAN DIERENDONCK JH, KEIJZER R, VAN DE VELDE CJH AND CORNELISSE CJ. (1989). Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. Cancer Res., 49, 2999-3006.
28. VERONESE SM, GAMBACORTA M, GOTTARDI O, SCANZI F, FERRARI M AND LAMPERTICO P. (1993). Proliferation index as a prognostic marker in breast cancer. Cancer, 71, 3926-3931.
29. VIELH P, CHEVILLARD S, MOSSERI V, DONATINI B AND MAGDELENAT H. (1990). Ki-67 Index and S-phase fraction in human breast carcinomas. Am. J. Clin. Pathol., 94, 681-686.
30. WALKER RA AND CAMPLEJOHN RS. (1988). Comparison of monoclonal antibody Ki-67 reactivity with grade and DNA flow cytometry of breast carcinomas. Br. J. Cancer, 57, 281-283.
31. WENGER CR, BEARDSLEE S, OWENS MA, POUNDS G, OLDAKER T, VENDELY P, PANDIAN MR, HARRINGTON D, CLARK GM AND McGUIRE WL. (1993). DNA ploidy, S-phase, and steroid receptors in more than 127 000 breast cancer patients. Breast Cancer Res. Treat., 28, 9-20.
32. WINTZER HO, ZIPFEL I, SCHULTE-MONTING J, HELLERICH U AND VON KLEIST S. (1991). Ki-67 immunostaining in human breast tumours and it's relationship to prognosis. Cancer, 67, 421-428.
33. ZAR JH. (1984). Biostatistical Analysis: Simple Linear Regression, Chapter 19, pp. 306-321. Prentice and Hall: New Jersey.